218 related articles for article (PubMed ID: 33297928)
1. MicroRNA-Mutant P53 Crosstalk in Chemoresistance: A Hint to Monitor Therapy Outcome.
Speciale A; Monti P; Fronza G; Izzotti A; Menichini P
Microrna; 2020; 9(5):322-335. PubMed ID: 33297928
[TBL] [Abstract][Full Text] [Related]
2. Negative regulation of the tumor suppressor p53 gene by microRNAs.
Kumar M; Lu Z; Takwi AA; Chen W; Callander NS; Ramos KS; Young KH; Li Y
Oncogene; 2011 Feb; 30(7):843-53. PubMed ID: 20935678
[TBL] [Abstract][Full Text] [Related]
3. The P53/microRNA network: A potential tumor suppressor with a role in anticancer therapy.
Sargolzaei J; Etemadi T; Alyasin A
Pharmacol Res; 2020 Oct; 160():105179. PubMed ID: 32890739
[TBL] [Abstract][Full Text] [Related]
4. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 Mediates Sensitivity to Cancer Treatment Agents in Oesophageal Adenocarcinoma Associated with MicroRNA and SLC7A11 Expression.
Eichelmann AK; Mayne GC; Chiam K; Due SL; Bastian I; Butz F; Wang T; Sykes PJ; Clemons NJ; Liu DS; Michael MZ; Karapetis CS; Hummel R; Watson DI; Hussey DJ
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074015
[No Abstract] [Full Text] [Related]
6. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Blandino G; Di Agostino S
J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
[TBL] [Abstract][Full Text] [Related]
7. Friend or Foe: MicroRNAs in the p53 network.
Luo Z; Cui R; Tili E; Croce C
Cancer Lett; 2018 Apr; 419():96-102. PubMed ID: 29330109
[TBL] [Abstract][Full Text] [Related]
8. Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis.
McCubrey JA; Lertpiriyapong K; Fitzgerald TL; Martelli AM; Cocco L; Rakus D; Gizak A; Libra M; Cervello M; Montalto G; Yang LV; Abrams SL; Steelman LS
Adv Biol Regul; 2017 Jan; 63():32-48. PubMed ID: 27776972
[TBL] [Abstract][Full Text] [Related]
9. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
10. The p53 miRNA interactome and its potential role in the cancer clinic.
Krell J; Frampton AE; Colombo T; Gall TM; De Giorgio A; Harding V; Stebbing J; Castellano L
Epigenomics; 2013 Aug; 5(4):417-28. PubMed ID: 23895654
[TBL] [Abstract][Full Text] [Related]
11. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres.
Ji Q; Hao X; Meng Y; Zhang M; Desano J; Fan D; Xu L
BMC Cancer; 2008 Sep; 8():266. PubMed ID: 18803879
[TBL] [Abstract][Full Text] [Related]
12. p53 shapes genome-wide and cell type-specific changes in microRNA expression during the human DNA damage response.
Hattori H; Janky R; Nietfeld W; Aerts S; Madan Babu M; Venkitaraman AR
Cell Cycle; 2014; 13(16):2572-86. PubMed ID: 25486198
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide small noncoding RNA profiling of pediatric high-grade gliomas reveals deregulation of several miRNAs, identifies downregulation of snoRNA cluster HBII-52 and delineates H3F3A and TP53 mutant-specific miRNAs and snoRNAs.
Jha P; Agrawal R; Pathak P; Kumar A; Purkait S; Mallik S; Suri V; Chand Sharma M; Gupta D; Suri A; Sharma BS; Julka PK; Kulshreshtha R; Sarkar C
Int J Cancer; 2015 Nov; 137(10):2343-53. PubMed ID: 25994230
[TBL] [Abstract][Full Text] [Related]
14. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
[TBL] [Abstract][Full Text] [Related]
15. Chaperoning the guardian of the genome. The two-faced role of molecular chaperones in p53 tumor suppressor action.
Wawrzynow B; Zylicz A; Zylicz M
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):161-174. PubMed ID: 29355591
[TBL] [Abstract][Full Text] [Related]
16. Genome-Wide Small RNA Sequencing Identifies MicroRNAs Deregulated in Non-Small Cell Lung Carcinoma Harboring Gain-of-Function Mutant p53.
Datta A; Das P; Dey S; Ghuwalewala S; Ghatak D; Alam SK; Chatterjee R; Roychoudhury S
Genes (Basel); 2019 Oct; 10(11):. PubMed ID: 31661871
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr Virus MicroRNA miR-BART5-3p Inhibits p53 Expression.
Zheng X; Wang J; Wei L; Peng Q; Gao Y; Fu Y; Lu Y; Qin Z; Zhang X; Lu J; Ou C; Li Z; Zhang X; Liu P; Xiong W; Li G; Yan Q; Ma J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209170
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs, wild-type and mutant p53: more questions than answers.
Jones M; Lal A
RNA Biol; 2012 Jun; 9(6):781-91. PubMed ID: 22664917
[TBL] [Abstract][Full Text] [Related]
19. miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression.
Li J; Chen Y; Zhao J; Kong F; Zhang Y
Cancer Lett; 2011 May; 304(1):52-9. PubMed ID: 21354697
[TBL] [Abstract][Full Text] [Related]
20. Transcriptome-wide characterization of the endogenous miR-34A-p53 tumor suppressor network.
Samuel N; Wilson G; Id Said B; Pan A; Deblois G; Fischer NW; Alexandrova R; Casallo G; Paton T; Lupien M; Gariepy J; Merico D; Hudson TJ; Malkin D
Oncotarget; 2016 Aug; 7(31):49611-49622. PubMed ID: 27391063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
